Source:http://linkedlifedata.com/resource/pubmed/id/17319449
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0006935,
umls-concept:C0024031,
umls-concept:C0034656,
umls-concept:C0039225,
umls-concept:C0066814,
umls-concept:C0087111,
umls-concept:C0205081,
umls-concept:C0205082,
umls-concept:C0205191,
umls-concept:C0206012,
umls-concept:C0282274,
umls-concept:C0441472,
umls-concept:C0722364,
umls-concept:C0724001,
umls-concept:C1096776,
umls-concept:C1170078,
umls-concept:C2603343
|
pubmed:issue |
3
|
pubmed:dateCreated |
2007-2-26
|
pubmed:abstractText |
This large, open-label, randomized, parallel-group, multicenter study compared two oral sustained-release opioids (SROs)--AVINZA (A-MQD), morphine sulfate extended-release capsules given once a day, and OxyContin (O-ER), oxycodone modified-release tablets given twice a day--in SRO-naive subjects ages 30 to 70 with chronic, moderate to severe low back pain. Of the 392 subjects enrolled and randomized, 266 (132 in the A-MQD group and 134 in the O-ER group) completed the opioid dose titration phase and entered an eight-week evaluation phase. During the evaluation phase, A-MQD achieved significantly better pain control than O-ER, as demonstrated by a greater decrease from baseline in pain scores obtained four times daily during weeks one, four, and eight (p = 0.002). The number of breakthrough-pain rescue medication doses adjusted for the number of patient days was significantly lower in the A-MQD group (p < 0.0001). Better pain control with A-MQD was achieved with a significantly lower daily opioid dose than with O-ER (mean 69.9 mg and 91 mg morphine equivalents, respectively; p = 0.0125). Quality of sleep was significantly better with A-MQD for the entire evaluation phase (p = 0.0026). The incidence and severity of elicited opioid side effects were similar in the two groups. This trial demonstrated that once-daily A-MQD provides consistent around-the-clock pain relief in patients with low back pain. In patients who completed opioid dose titration, A-MQD was significantly better than O-ER for reducing pain and improving sleep, while requiring a lower daily opioid dose.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/Capsules,
http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations,
http://linkedlifedata.com/resource/pubmed/chemical/Morphine,
http://linkedlifedata.com/resource/pubmed/chemical/Oxycodone
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1551-7489
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
155-66
|
pubmed:meshHeading |
pubmed-meshheading:17319449-Administration, Oral,
pubmed-meshheading:17319449-Adult,
pubmed-meshheading:17319449-Aged,
pubmed-meshheading:17319449-Analgesics, Opioid,
pubmed-meshheading:17319449-Capsules,
pubmed-meshheading:17319449-Delayed-Action Preparations,
pubmed-meshheading:17319449-Female,
pubmed-meshheading:17319449-Humans,
pubmed-meshheading:17319449-Low Back Pain,
pubmed-meshheading:17319449-Male,
pubmed-meshheading:17319449-Middle Aged,
pubmed-meshheading:17319449-Morphine,
pubmed-meshheading:17319449-Opioid-Related Disorders,
pubmed-meshheading:17319449-Oxycodone,
pubmed-meshheading:17319449-Sleep
|
pubmed:articleTitle |
The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain.
|
pubmed:affiliation |
Carolinas Pain Institute, Winston-Salem, North Carolina, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|